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A common complication of Human Immunodeficiency Virus (HIV) and anti-retroviral therapy (ART) is 
distal sensory polyneuropathy (DSP). Older age and previous TB are risk factors for DSP among HIV-
infected Africans before and shortly after ART initiation. Little is known about autonomic dysfunction in 
Africans on long-term ART and the impact of DSP and autonomic impairment on their quality of life. Our 
aim was to describe the frequency, characteristics and functional consequences of DSP and autonomic 
dysfunction in a healthy HIV-infected community-based cohort after at least 5 years of ART.  
Methods 
HIV-infected South Africans on the government-sponsored ART program for at least 5 years were 
included in this cross-sectional analysis. Each consenting participant underwent a focussed neurological 
assessment using the Brief Peripheral Neuropathy Screen (BPNS) and a reduced version of the Total 
Neuropathy Score (rTNS). DSP was defined as the presence of at least 2 neuropathic signs in a distal and 
symmetrical distribution, and symptomatic DSP (SDSP) when accompanied by neuropathic symptoms. 
Heart rate variability and orthostatic hypotension were measured as described by the Ewing classic 
battery, and the Survey of Autonomic Symptoms (SAS) questionnaire assessed the presence and severity 
of autonomic symptoms. We used a modified version of the Lower Extremity Functional Scale (LEFS) to 
assess lower limb physical ability. 
Results 
The 67 participants had a median age of 41 years (interquartile range (IQR) 36-46) and 61 (91 %) were 
women. The median duration of ART was 7 years (IQR 6-10). DSP criteria were met in 54 (80.6%) and 24 
(44.4%) had symptomatic DSP. Comparing participants with DSP to those without DSP, there was no 
difference in sex (P=0.39), age (P=0.79), current CD4 (P=0.69), viral suppression (P=0.34), ART duration 
(P=0.22) or previous tuberculosis (TB) (P=0.72) in those with DSP. Similar outcomes were obtained for 
SDSP. Abnormal autonomic tests were present in 60%. Those with SDSP had more severe autonomic 
symptoms than those with asymptomatic DSP (P=0.0008). We found that those with DSP and SDSP had 




DSP remains a common complication of HIV in the modern era of ART and can lead to significant 
functional impairment. Autonomic dysfunction is prevalent in SDSP. 
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Introduction and Literature Review 
HIV-associated distal sensory polyneuropathy (DSP) is a common complication of HIV and its treatment 
1–5. In 2016, an estimated 6.1 million South Africans were living with HIV, 56% of whom were on 
antiretroviral therapy (ART)6. This number is expected to increase since the national implementation of 
the ‘Universal Test and Treat’ policy in South Africa in September 20167: ART is now available to all HIV-
infected individuals regardless of CD4 count or staging. People with HIV are living longer and clinicians 
are now facing an aging HIV-positive population who are presenting with non-communicable illnesses 
that may be related to long-term ART, chronic inflammation or immune activation 8. Some have shown 
that HIV-infected patients are more at risk of developing DSP before or within the first 3 to 6 months of 
ART 5,8,9. However, HIV-associated DSP, in the setting of long-term ART in African populations, is a topic 
that is poorly studied.  
HIV-associated DSP occurs in two clinical contexts:  as a direct consequence of HIV infection or as an 
adverse effect of ART, also termed antiretroviral toxic neuropathy 1,8,10,11. Common symptoms of DSP are 
numbness, burning sensation, and stabbing pain in the feet and lower extremities 1. Painful DSP can 
result in psychological distress and physical disability; thereby adversely affecting quality of life12,13. 
Furthermore, neuropathic pain is usually not alleviated by regular analgesia10,14,15. A South African-based 
cross-sectional study by Maritz et al demonstrated that the frequency of symptomatic DSP was 23% in 
ART-naïve individuals compared to 40% in the ART- and 36% in the stavudine (D4T)-exposed patients 
with more advanced HIV disease (Maritz et al., 2010). However, results recently obtained in a South 
African cohort followed from pre-ART initiation to 2 years on D4T- or tenofovir (TDF)-based regimens 
showed that neuropathic symptom prevalence did not differ significantly between the two ART 
regimens and in fact largely improved on ART in both groups 5.  
Older age is frequently cited as a risk factor for DSP amongst the ART-exposed 1–3,5,10,14–18. With an 
increased lifespan on effective ART, one must anticipate that the aging South African HIV positive 
population will be faced with this troubling complication. Female sex and previous tuberculosis (TB) are 
also mentioned as risk factors for DSP in the ART-exposed 1,2,5,10. Mitochondrial toxicity is implicated in 
the pathophysiology of antiretroviral toxic neuropathy 8,11. The dideoxynucleoside reverse transcriptase 
inhibitors (dNRTIs) - stavudine and didanosine – were considered the chief culprits 2,3,17,19, both of which 
were used in Sub-Saharan Africa until 2010 when national ART guidelines changed first line ART from 
12 
 
D4T to TDF-based regimens20. It remains to be seen whether this change has been truly beneficial to 
those at risk of DSP. 
Functional Impairment in HIV-infected subjects with DSP 
As the incidence of opportunistic diseases and mortality continue to decline in the era of ART, quality of 
daily living must remain an important goal of therapy in this aging HIV-positive population. There is little 
data about functional impairment and quality of life of those who are affected by HIV-associated DSP, 
particularly in Sub-Saharan Africans. In Rwanda, 185 HIV-infected participants (mean age of 38.7 years; 
SD ± 9.6 ) were asked whether DSP affects quality of life 13. Physical and psychological quality of life was 
found to be significantly lower in those with DSP than those without DSP.  This cohort consisted of both 
ART-exposed (duration unknown) and ART-naïve patients making it difficult to apply these outcomes to 
our population on long-term ART. An American Study by Galantino et al found that participants with 
HIV-associated DSP had significantly lower scores on lower limb function questionnaires and quality of 
life screening tools than HIV-positive patients without DSP 15. Additionally, 80% of those with DSP were 
likely to seek medical treatment for pain compared to the 11% without DSP supporting the notion that 
symptomatic DSP negatively affects daily living. All of these participants were receiving ART, had 
relatively preserved CD4 counts and had similar clinical and demographic characteristics. The mean age 
of those with DSP was 42 years. The scoring questionnaire used by Galantino et al - the Lower Extremity 
Functional Scale (LEFS, explained later) - was found to be highly predictive of physical and mental quality 
of life in patients with HIV-associated DSP.   
Consequently, it is imperative for clinicians to understand how DSP can impact the lives of patients so 
that early identification and intervention can occur.  
Autonomic Dysfunction in HIV-infected subjects with DSP 
Early studies showed autonomic dysfunction in African and non-African patients with advanced HIV or 
untreated disease21–23. However, the presence of autonomic dysfunction in African medically stable 
patients established on long-term ART has been scarcely described. In the last decade Robinson-Papp et 
al found autonomic dysfunction in 61% of HIV-positive American patients  with a median CD4 count of 
439 cells/µL, most (95%) of who were on ART with suppressed viral loads, yet there was no association 
between autonomic dysfunction and ART in this group 24. Features of autonomic dysfunction include 
orthostatic hypotension, decreased heart rate variability, sleep dysfunction, altered sweating, 
constipation or diarrhoea, nausea and vomiting, impotence and bladder dysfunction. These symptoms 
13 
have the potential to be debilitating. Moreover, there is an association between cardio-autonomic 
dysfunction and increased mortality in diabetic subjects25,26. These deleterious characteristics of 
autonomic dysfunction highlight the importance of exploring this topic in the context of HIV patients 
who are now living longer on ART.  Two European studies assessed autonomic dysfunction in HIV-
positive outpatients on ART compared to HIV negative controls and found an increased resting heart 
rate and decreased heart rate variability demonstrating impaired parasympathetic tone in the HIV-
positive group27,28. Both studies evaluated patients with median CD4 counts above 500 and on ART for a 
median of 7 years, most (> 90%) of whom had suppressed viral loads. These characteristics and the 
comparison to age- and sex-matched controls make both studies decidedly relevant in discerning 
autonomic dysfunction in the setting of long-term ART.  Limitations were the small sample size and the 
cross-sectional nature of both studies. McIntosh et al reinforced the concept of autonomic dysfunction 
in the era of ART in a meta-analysis describing decreased heart rate variability in HIV-positive individuals 
on ART compared to HIV-negative controls 29. With the exception of Robinson-Papp et al, all of the 
aforementioned studies excluded diabetic patients in order to limit confounding factors. Except for a 
small sub-group of studies within the meta-analysis, those on anti-hypertensive medication were also 
excluded. Most studies tend to focus on cardio-autonomic testing with little or no attention to the other 
autonomic domains. One study used the Autonomic Symptom Profile (ASP) – a 169-item questionnaire 
of 11 autonomic domains – and found that 40% of HIV-positive virologically suppressed patients had 
symptoms of autonomic dysfunction compared to 9% of HIV-negative controls 30. This group classified 
this finding as clinically significant autonomic neuropathy. However, the completion of a 169-item 
questionnaire is time-consuming and not practical in a South African setting. The authors believe that 
the addition of simple autonomic symptom questionnaire, encompassing all domains, may provide a 
simple, yet comprehensive evaluation of autonomic dysfunction in the healthy, ART-exposed 
population.  
It is well known that peripheral neuropathy, particularly small fiber neuropathy, can be accompanied by 
autonomic neuropathy, as is the case with diabetic and alcoholic peripheral neuropathy. There is limited 
data on the relationship between autonomic neuropathy and HIV-associated DSP. Rogstad et al did not 
find any correlation between autonomic dysfunction and HIV-associated neurological disease in ART-
naïve African patients 22. However, the previously mentioned study by Robinson-Papp et al found those 
with severe DSP (Total Neuropathy Score (TNS) ≥15) were 3-times more likely to have autonomic 
symptoms and/or signs compared to those with little or no DSP (TNS<4) 24. Another study also found 
significantly lower sweat volumes (as defined by the quantitative sudomotor axon reflex test) in ART-
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exposed patients, a majority of whom were virologically suppressed, with neuropathy compared to 
those without neuropathy 31. Further research about the presence of autonomic symptoms in ART-
exposed patients, their severity and their impact on quality of life is needed. It would therefore be 
important to explore autonomic neuropathy in the ART-treated population so that screening and 
treatment strategies can be instituted. 
 
In this cross-sectional study we aimed to assess the frequency and severity of neuropathy and 
autonomic dysfunction, as well as the impact on daily function in healthy HIV-infected Africans after at 
least 5 years of ART.  
Chapter 2 
Methods 
Study Design and Population 
Ambulant, community-based HIV-positive patients were recruited from a community health care center 
in Crossroads, Cape Town. Subjects were eligible for inclusion if they were HIV-positive, ≥18 years, on 
ART for at least 5 years and were clinically well. Subjects were excluded if they had an active 
opportunistic infection, current anti-tuberculosis therapy of less than 1 month duration, liver or renal 
failure, or active alcohol or substance misuse. All participants provided written informed consent prior 
to assessment 32. This study was approved by the University of Cape Town Research Ethics Committee 
(HREC REF 221/2008 and HREC REF 200/2017).  
Participant Assessment 
Participant assessment was conducted over 2 consecutive days. A trained Xhosa speaking fieldworker 
was present during these assessments as Xhosa is the predominant language of the study participants. 
Patient demographics, height and weight were recorded.  A comprehensive medical history of 
participant habits, co-morbid disease, pregnancy and medication (including ART) usage was taken. 
Recent viral load (taken within 3 months of the study visit) and CD4 count (taken within 6 months of the 
study visit) were obtained from the national lab results system.  Each participant had the following 
blood tests in a fasting state: oral glucose tolerance test (OGTT), fasting lipogram, serum creatinine and 




A focussed neuropathy examination was performed by a clinician (SM, CD, MB or MD) under the direct 
supervision of a neurologist (JMH). A medical examination was performed by a specialist physician (MB) 
to exclude any intercurrent illness. Cardio-autonomic testing (conducted by MB) occurred on the second 
day and included RR interval change (which reflects heart rate variability) and orthostatic hypotension.  
The neuropathy assessment comprised the Brief Peripheral Neuropathy Screen (BPNS) and reduced 
Total Neuropathy Score (TNSr) as previously described by Maritz et al10. The performance characteristics 
of these tools has been discussed elsewhere18,21,33,34. All questionnaires were in English and Xhosa 10.  
The sensory symptoms evaluated by the BPNS are symmetrical neuropathic pain, numbness and “pins-
and-needles”. These symptoms are graded on a numerical rating scale (NRS) from 1 (mild) to 10 
(severe). The total BPNS sensory severity grade is the single highest NRS value of any of the 3 symptoms.  
Vibration at the terminal hallux (using a 128 Hz tuning fork) and ankle reflexes are the two examination 
domains evaluated by the BPNS. Vibration was scored from 0 (vibration felt for >10 second, or normal) 
to 3 (no feeling of vibration). Ankle reflexes were scored from 0 (clonus) to 4 (absent) with a middle 
score of 2 indicating normal reflexes.   
The TNSr assesses sensory symptoms, pin sensibility, vibration sensibility, deep tendon reflexes and 
muscle strength in a quantitative fashion. It aims to describe the extent of limb involvement from 0 (no 
abnormality) to 4 (symptom/sign extending above knee/elbow or complete paralysis). Proprioception 
(i.e. joint position sense) is not part of either of these neuropathy scoring systems, but was included in 
our assessment of these patients. Proprioception measured at the terminal hallux was assessed in a 
series of 10 trials and then defined as either normal, reduced (>2/10 mistakes) or absent.  All abnormal 
scores required bilateral limb involvement to be classified as DSP.  
For the purposes of this study, DSP is defined as the presence of at least 2 of the following neuropathic 
signs in a distal and symmetrical distribution: decreased vibration, or altered proprioception, or 
decreased deep tendon reflexes, or weakness in the ankle and toes,  or decreased pin sensibility. 
Symptomatic DSP is defined as 2 signs plus any 1 neuropathic symptom, viz. paraesthesia, numbness or 
pain.  Patients are classified as asymptomatic if they have 2 signs without any symptoms.  
The Lower Extremity Functional Scale (LEFS) comprises 20 questions that centers on day-to-day lower 
limb physical ability. This was originally developed to assess disability in patients with neuromuscular 
disorders 15 in higher income countries. We used a version of the LEFS that has been validated in an 
African setting and modified to suit the activities of daily living of patients from lower income 
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countries35. Each activity is subjectively ranked from 0 (extreme difficulty) to 4 (no difficulty) to attain a 
total out of 80. During data analysis, we used a percentage score with 100% reflecting no difficulty in 
activity.  
The Survey of Autonomic Symptoms (SAS) is a valid, easily administered questionnaire that can be used 
in clinical trials assessing autonomic symptoms 36. It was found to have a greater sensitivity and 
specificity than the ASP for autonomic symptoms in early diabetic neuropathy36. The SAS consists of 11 
questions for women and 12 for men. It focuses on the presence and degree of severity of autonomic 
symptoms of the following domains: orthostatic, secretomotor, vasomotor, gastrointestinal, urinary, 
and male sexual dysfunction. Each item is graded on a severity score ranging from 1 (absent) to 5 
(severe). The severity scores for each symptom are added up to give a total impact score. Zilliox et al 
applied the SAS in diabetics with neuropathy and age-matched healthy controls, and found >3 
symptoms would provide > 90% specificity and 65% sensitivity in determining autonomic dysfunction, 
and a total impact score (TIS) of > 7 would provide > 90% specificity and > 60% sensitivity in determining 
autonomic symptom severity 36.  These cut-offs were applied to the participants of this study. 
We developed a reduced Composite Autonomic Score (CASr) (figure 1), inspired by the Composite 
Autonomic Severity Score (CASS) defined in Low et al 24, to describe autonomic dysfunction in our study 
population.  It comprised of 3 parameters each contributing 1 point if present: abnormal heart rate 
variability, orthostatic hypotension, and a significant SAS (> 3 symptoms) or TIS (> 7).  All participants 
were instructed to fast for ≥8 hours prior to testing and thus would have no coffee or medication on the 
morning of the 2nd day of assessment. Heart rate variability and orthostatic hypotension were measured 
as described by the Ewing classic battery 37.  Heart rate response to moving from a lying to standing was 
assessed by measuring the the beat to beat (R–R) interval change during this change in position. An R-R 
interval ratio of ≤ 1.04 was abnormal. Orthostatic hypotension was measured and defined in the 
conventional method: drop in SBP of ≥ 20mmHg or DBP ≥10mmHg when moving from lying position to 
standing after 2 mins. We also enquired about symptoms of dizziness and palpitations while these 




Statistical analysis was performed using Excel, Graph Pad (version 7), OpenEpi (www.openepi.com) and 
STATA 14.1 (Stata Corp, College Station, Texas). Variables were reported based on their normality; 
means (±SD) and medians (IQR) - normal and skewed data respectively. The difference between 
proportions was tested using the Z-test for proportions. The Student T-test was used for continuous, 
normally distributed variables, e.g. amongst participants with DSP versus those without DSP (see table 
1). The non-parametric Mann-Whitney U test was used for group comparisons in skewed continuous 
variables. Graphical presentation of the different scores was done using Graph Pad. A p-value of ≤0.05 





Sixty-nine patients were enrolled into this study from August 2014 to December 2016. Two were 
excluded-; one had defaulted ART and was intoxicated with alcohol on the second day of examination, 
and another had only been on ART for 2 years. Of the 67 remaining participants one participant did not 
attend the second day of testing and had missing autonomic data, fasting blood tests and information 
about the ART regimen.   
The characteristics of the study cohort are shown in Table 1. Of the 67 participants, 91% were female 
with a mean age of 41.6 years (standard deviation (±SD) 8.6). All participants were black Africans. The 
median time on ART was 7 years (IQR 6-10) and the mean CD4 count was 560 cells/µL (±SD 236.5). Fifty-
1 
Figure 1 The Reduced Composite Autonomic Score 
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six (84%) of the participants were virologically suppressed, defined as < 400 copies/ml by the HIV 
Research Network 38. Thirty-nine (58%) had a prior history of TB. Fifty (75%) patients took tenofovir-
based regimens; 13 (19%) were on zidovudine-based regimens, and 3 (4%) were on stavudine-based 
regimens. No patients were taking didanosine. Fifty-seven (85%) participants had had a change in their 
ART regimen since initiating ART. The reasons supplied for the change included virological failure (13), 
drug side-effects (10), pregnancy (1) and for convenience (29) with a switch from 3 drugs to a fixed-dose 
combination.  Four participants could not recall why they were switched. Two patients were using 
cotrimoxazole (Bactrim) prohylaxis. Fourteen were using isoniazid prophylaxis but only 5 of these 
patients were taking vitamin B6 supplementation. Eight patients were taking anti-hypertensive agents: 
six were on a single agent; two were on 2 agents. 








Women, N (%) 61 (91) 50 (92.6) 11(84.6) 0.37* 
Age (years),  mean (±SD) 41.6 (8.6) 41.8 (8.7) 41.1(8.5 ) 0.79ᶧ 
Previous TB, N (%) 39 (58.2) 32 (59.3) 7 (53.9) 0.72* 
Weight (kg),  mean (±SD) 71.3 (16.3) 70.3 (15.5) 75.7 (19.3) 0.28ᶧ 
Height (m), median (IQR) 1.59 (1.55-1.63) 1.60 (1.55-1.63) 1.56 (1.55-1.62) 0.42ˠ 
Current CD4 (cells/uL), mean 
(±SD) 
560.2 (236.5) 566.7 (247.1) 536.8 (200.2) 0.69ᶧ 
Viral suppression, N (%) 56 (83.6) 44 (81.5) 12 (92.3) 0.34* 
Viral load <20 copies/ml , N % 50 (74.6) 38 (70.4) 12 (92.3) 0.10* 
ART duration (years), median 
(IQR) 
7 (6-10) 7.5 (6-10) 7 (5-9) 0.22ˠ 
D-Drugs, N (%) 3 (4.5) 3 (5.6) 0 0.38* 
Efavirenz, N (%) 34 (50.8) 30 (55.6) 4 (30.8) 0.11* 
Isoniazid, N (%) 14 (20.9) 9 (16.7) 5 (38.5) 0.08* 
DSP, distal sensory polyneuropathy; SD, standard deviation; TB, tuberculosis; IQR, interquartile range; 
viral suppression refers to <400 copies/ml; ART, anti-retro viral therapy; D-Drugs, dideoxynucleoside 
reverse transcriptase inhibitors e.g. Stavudine (D4T) or didanosine (DDI); P-values derived by *z-test, ᶧt-
test, ˠMann-Whitney 
Frequency and Characteristics of DSP 
Most (81%) of the participants met criteria for DSP arbitrarily defined as the presence of 2 neuropathic 
signs. Indeed, 66 of the 67 participants had at least one symmetrical neuropathic sign. The 
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characteristics of patients with and without DSP are shown in Table 1. The median time on ART was 7.5 
years (IQR 6-10).  The mean age of those with DSP was 41.8 years (±SD 8.7) and the median CD4 count 
was 567 cell s/µL (±SD 247.1). Most (81%) of those with DSP were virologically suppressed. Compared 
with participants without DSP, there was no difference in: sex (P=0.37), age (P=0.79), current CD4 
(P=0.69), viral suppression (P=0.34), ART duration (P=0.22), previous TB (P=0.72) and hsCRP (P= 0.44). Of 
the 9 Isoniazid-users who were not on Vitamin B6 supplements, the majority (67%) had DSP but this was 
not statistically significant (P=0.83). There was a trend towards an association between current isoniazid 
use and DSP (P=0.08). None of the metabolic or anthropometric parameters, including body mass index 
(BMI), were associated with the presence of DSP (see supplementary table 1). As the frequency of DSP 
was so high based on an arbitrary definition of 2 neuropathic signs, we also used a more stringent 
definition for DSP of ≥3 signs to determine if this would significantly alter our results. With the exception 
of previous TB, these differences did not alter when we used this alternative definition (see 
supplementary table 2). Previous TB tended to be more common in those with DSP-3 signs (68 vs. 47%, 
P=0.08).  
Frequency and Characteristics of Neuropathic Symptoms and SDSP 
Amongst the total cohort, the most frequent symptom was numbness (31 %) followed by pain, aching 
and burning (30%) and then “pins-and-needles” (28%) (see table 2). Figure 2 shows the range of 
symptom severity according to the BPNS. Most participants described moderate to moderately severe 
symptoms (NRS ranging from 4 to 8). Despite this only 4 patients were prescribed medication for relief 
of their neuropathic pain: 3 used amitriptyline and one paracetamol. The most common neuropathic 
signs in the total cohort were: decreased pin sensibility and deep tendon reflexes (79%). Impaired 
vibration (49%) and proprioception sense (40%) were also prevalent. There was only 1 patient who had 
mild decreased power at the ankle and toes. This patient also had impaired vibration sense, deep 
tendon reflexes, pin sensibility and had a high BPNS total sensory severity grade of 4 (NRS between 9-
10). Most patients were asymptomtomatic with a NRS of 0 (see figure 2). Figure 3 shows the TNSr score 
spread across the entire cohort, with a median score of 6 (IQR 4-8) out of a total of 20 implying that the 
anatomical extent of disability was limited to the distal regions. 
SDSP was present in 24 (44%) of those with DSP (see supplementary table 3). The frequency of 
neuropathic signs were: impaired deep tendon reflexes (100%) followed by altered pin sensibility (92%), 
proprioception (63%), and vibration (58%) (see table 2). Comparing participants with SDSP and ADSP, 
there was no difference in: sex (P=0.20), age (P=0.61); current CD4 (P=0.27); viral suppression (P=0.70), 
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ART duration (P=0.85), previous TB (P=0.32), hsCRP (P= 0.26), or the use of efavirenz (P=0.75) and 
isoniazid (P=0.46). None of the metabolic or anthropometric parameters were associated with the 
presence of SDSP. 
We measured serum vitamin B12 in 26 of the 27 patients with impaired proprioception (one specimen 
was misplaced): none had values below the normal laboratory reference range of 138 pmol/L. The mean 
serum vitamin B12 amongst those with impaired proprioception was 365 pmol/L (SD± 127.3).  
Table 2 Comparative frequency and severity of neuropathic clinical features 







Neuropathic Feature  n (%) n (%) Severity*  
median (IQR) 
n (%)  
Pain, aching, burning 20 (29.9) 16 (66.7) 5 (3.8-6.3) -  
“Pins-and-Needles” 19 (28.4) 14 (58.3) 4 (3-6.8) -  
Numbness  21 (31.3) 17 (70.8) 4 (3-6) -  
Impaired Vibration 33 (49.3) 14 (58.3) - 19 (63.3) 0.71 
Reduced/absent Reflexes 53 (79.1) 24 (100) - 30 (100) 1.00 
Decreased Pin Sensibility 53 (79.1) 22 (91.7) - 27 (90) 0.83 
Impaired Proprioception 27 (40.3) 15 (62.5) - 12 (40) 0.10 
Decreased Distal Power 1 (1.5) 1 (4.2) - 0 0.26 
SDSP, symptomatic distal sensory polyneuropathy; ADSP, asymptomatic distal sensory polyneuropathy; 
IQR, interquartile range ; *Severity according to Brief Peripheral Neuropathy Screen (BPNS) numerical 










Figure 4 illustrates the frequency of abnormal CASr in the total cohort. A majority (60%) of the cohort 
attained a positive CASr (i.e. at least 1 out of 3 points). Half of these participants scored significantly in 
the SAS or TIS only; 25% had only cardio-autonomic signs (i.e. abnormal heart rate variability and 
orthostatic hypotension) and the other 25% had both cardio-autonomic and significant scores for SAS or 
TIS. Two participants had diabetes and only one of these had a positive CASr. Of those who had a 
positive CASr, 5 (13%) participants achieved the maximum score of 3, 6 (15%) achieved a score of 2, and 
29 (73%) achieved a score of 1.   
Ten patients exhibited a postural drop in blood pressure; half of these patients had associated 
symptoms. The most common symptoms reported were light-headedness (49%) and cold feet (39%) 
(table 3). The least common symptoms were erectile dysfunction (5%), persistent diarrhea (8%) and 
increased sweating in hands (9%).  None of the participants had more than 7 (out of the 12) autonomic 
symptoms present (see figure 5). Most participants had either 0, 2 or 4 symptoms present.  The severity 
scores were relatively low amongst the cohort, with most of the symptomatic patients scoring a TIS of 2 
Figure 2 Distribution of the Brief Peripheral Neuropathy Screen (BPNS) total sensory severity grade amongst the total 
cohort.  The total grade is determined by the highest points assigned to each symptom on a numerical rating scale 
(NRS) of 1 (mild) to 10 (severe). Grade 0 refers to no symptoms; Grade 1 refers to NRS 2-3; Grade 2 refers to NRS 4-6; 
Grade 3 refers to NRS 7-8; Grade 4 refers to NRS 9-10.  
Figure 3 Distribution of the reduced Total Neuropathy Score (TNSr) for the entire cohort. The total score (out of 20) 
represents the anatomical extent of the 5 symptoms and signs. Each symptom and sign is graded from 1 (only in 




(out 60 for men and 55 for women) (see figure 6). Anticholinergics, diuretics, beta blockers and alpha 
blockers can potentially affect autonomic tests (Robinson-Papp, Sharma, Simpson, & Morgello, 2013). It 
is important to note that 2 of the patients with postural hypotension were taking anti-hypertensive 
medication, and another 2 were on tricyclic agents. A third patient taking a tricyclic agent also had 























Figure 4 Distribution of the reduced Composite Autonomic Score (CASr) according to Survey of Autonomic 
Symptoms (SAS) or Total Impact Score, and cardio-autonomic (CA) signs amongst the total cohort. Positive CASr= 1 









CA signs + SAS/TIS 
N=10 (25%) 





HRV + Postural hypotension 
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Table 3 Frequency and severity of each autonomic symptom amongst the total cohort. Each symptom is 
scored on severity scale from 1 (absent) to 5(severe). 




Light headedness 33 (49.3) 3 (2-3) 
Dry mouth/dry eyes 17 (25.4) 2 (1-2) 
Blue or pale feet 12 (17.9) 3 (2-4) 
Colder feet 26 (38.8) 4 (2-5) 
Decreased sweating in feet 14 (20.9) 2 (1-2) 
Decreased/absent sweating in feet after 
exercise 
13 (19.4) 2 (1-2) 
Increased sweating in hands 6 (9) 2 (1-2) 
Nausea, vomiting, bloating after small meal 14 (20.9) 2 (2-3) 
Persistent diarrhoea 5 (7.5) 2 (1-3) 
Persistent constipation 16 (23.9) 2 (1-4) 
Urinary incontinence 9 (13.4) 2 (1-3) 
Erectile Dysfunction* 3 (4.5) 4 (3-5) 










Figure 5 Number of autonomic symptoms that were present amongst the total cohort. The dotted line represents the 
median*.  SAS, survey of autonomic symptoms 
Figure 6 Frequency of the severity scores (TIS, total impact score ) amongst the total cohort. The dotted line represents 
the median*. 















SAS score, median (IQR) 2 (1-4) 2 (1-4) 1 (0-4) 0.22ˠ 
SAS total impact score, median (IQR) 6 (1-10.5) 6.5 (2-10.8) 2 (0-8) 0.18ˠ 
Signs 
Abnormal Heart rate variability, N (%) 16 (23.9) 14 (25.9) 2 (15.4) 0.42* 
Postural hypotension, N (%) 10 (14.9) 10 (18.5) 0 0.09* 
CAS, N (%) 38 (56.7) 32 (59.3) 6 (46.2) 0.4* 
DSP, distal sensory polyneuropathy;  SAS, survey of autonomic symptoms; IQR, interquartile range; CAS, 
composite autonomic score; P-values derived by *z-test, ˠMann-Whitney 
 
Table 4 shows that there was no correlation between DSP-2signs and the presence of autonomic 
symptoms (P= ≥ 0.18) or abnormal heart rate variability (P= 0.42), but there was a trend towards an 
association with postural hypotension (P=0.09). Those with SDSP showed a trend towards having more 
autonomic symptoms (median 4; IQR 1-5) compared to those with ADSP (median 2; IQR 1-3; P=0.063) 
(see supplementary table S3). Those with SDSP also had significantly higher TIS than those with ADSP 
(median score 10; IQR 2.8-15 vs median score 3; IQR 2-7.8; P=0.0008). There was a moderate correlation 
between ART duration and the SAS which was statistically significant (r=0.34, P=0.002) (see 
supplementary figure 3). Thus, those with autonomic symptoms were more likely to have SDSP and 
longer exposure to ART.  
Functional Impairment associated with DSP and Autonomic Dysfunction 
In order to assess whether the presence of DSP is functionally relevant in a patient’s daily life, we asked 
each participant to complete the LEFS questionnaire.  Three participants did not complete the LEFS. Only 
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one participant obtained a LEFS score of less than 50%. This participant, who had an LEFS score of 
47.5%, also had SDSP and a high CASr score of 3. Table 5 demonstrates the LEFS activities that were 
most frequently impaired amongst the cohort. Overall, we found that those with DSP had significantly 
lower LEFS percentage scores than those without DSP (93.8% vs 100%; IQR 94.4-100; P=0.039) (see 
figure S4), and those with SDSP had lower scores than ADSP (88.8% vs 96.3%; IQR 90.0-98.8; P=0.04) 
(see table S3).   
There was a moderate negative correlation between LEFS and CASr (r=-0.36; P=0.0035) (see figure S5), 
but a stronger negative correlation between autonomic severity scores and LEFS (r=-0.59; P=<0.001) 
(see figure S6). Interestingly, the LEFS correlated stronger with the BPNS symptom severity (r=-0.46; 
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Table 5 Frequency of impaired LEFS activities amongst the total cohort, DSP 2-signs and SDSP   






Occupation or school 
work 
13 (19.4) 12 (22.2)  6 (25) 
Hobbies e.g. going to 
church 
5 (7.5) 5 (9.3) 4 (16.7) 
Taking a bath 3 (4.5) 3 (5.6) 2 (8.3) 
Walking from room to 
room 
4 (6) 3 (5.6) 2 (8.3) 
Putting on shoes or 
socks 
6 (9) 6 (11.1) 4 (16.7) 
Squatting 11 (16.4) 10 (18.5) 6 (25) 
Lifting object from floor 12 (17.9) 9 (16.7) 3 (12.5) 
Light housework 3 (4.5) 3 (5.6) 2 (8.3) 
Heavy activities  22 (32.8) 19 (35.2) 11 (45.8) 
Getting into/out of 
car/taxi 
7 (10.4) 6 (9) 4 (16.7) 
Walking from your 
home to neighbours’ 
7 (10.4) 6 (11.1) 4 (16.7) 
Walking to shop or 
church 
14 (20.9) 12 (22.2) 8 (33.3) 
Going up/down 10 
stairs or steep hill 
29 (43.3) 24 (44.4) 13 (54.2) 
Standing for 1 hour 22 (32.8) 20 (37) 13 (54.2) 
Sitting for 1 hour 10 (14.9) 9 (16.7) 7 (29.2) 
Fast walking on even 
ground 
20 (29.9) 19 (35.2) 9 (37.5) 
Fast walking on uneven 
ground 
29 (43.3) 25 (46.3) 11 (45.8) 
Making sharp turns 
while walking/running 
22 (32.8) 21 (38.9) 12 (50) 
Standing up fast from 
squatting 
21 (31.3) 18 (33.3) 11 (45.8) 
Turning in bed 8 (11.9) 8 (14.8) 6 (25) 
Figures represented as N(%); LEFS, lower extremity functional scale; DSP, distal sensory polyneuropathy; 
SDSP, symptomatic distal sensory polyneuropathy 
Chapter 4 
Discussion     
In this African cohort of 67 healthy HIV-infected patients on ART for at least 5 years, most of whom were 
virologically suppressed and not using dNRTI, DSP remains common. Using a stringent definition of DSP 
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that includes 2 neuropathic signs, 81% of participants had DSP. This is considerably higher than the 
prevalence of 60% in a similar South African D4T-exposed cohort 10 with DSP defined as 2 neuropathic 
signs on ART for a median of only 14 months. Most (59%) of those with DSP had previous TB which can 
serve as marker of advanced HIV before or shortly after ART initiation. This apparent severity of HIV at 
the start of ART may explain the high prevalence of DSP in our cohort.  
Age was not associated with the presence of DSP or SDSP in our study population. Our small sample size, 
narrow age range (SD 8.6 years) and prevalent neuropathy status may account for this. Previous TB had 
only a marginal association with DSP when the definition of 3 neuropathic signs was used. This may 
suggest that only the more severe neuropathy cases were associated with previous TB. Despite the 
significant number of participants on Isoniazid without Vitamin B6, there was no association between 
the lack of this supplement and DSP. However, the total number of INH-users was small making this 
observation inconsequential. BMI, mean SBP and high triglyceride levels were previously found to be 
associated with DSP in pre-ART South African populations 5,10 but this was not reproduced in this cohort 
who had been on effective ART for more than 6 years.   
Almost half (44%) of those with DSP were symptomatic. Interestingly, only 2 patients with SDSP used 
analgesia, viz. amitriptyline. This may indicate that SDSP is not well recognized by clinicians treating 
these healthy ART-experienced patients, and is thus under-treated. This prospect is quite disconcerting 
in view of our finding that LEFS scores are lower in SDSP than those without neuropathic symptoms, 
indicating that these symptoms do impact daily living. 
Our study found proprioception dysfunction in 40% after 7 years of ART. In a similar African cohort, 
Center et al found that the frequency of altered toe proprioception was 2% (in 102 individuals) after 2 
years of ART.  The reason for this substantial difference is unclear. Vitamin B12 deficiency was excluded 
as a confounder in our cohort. Interestingly, Centner et al also found that the prevalence of other large 
fiber signs (reflexes and vibration) increased after 2 years 5. Proprioception is not usually assessed in HIV 
neuropathy studies and our result suggests that it may be important to use this modality to assess large 
fiber dysfunction in patients on long term ART. 
 
Abnormal autonomic tests, particularly the SAS, were quite prevalent in this relatively young ART-
exposed group. It is important to note that most of these patients were not taking medications that 
could affect the results of these autonomic tests.  High prevalence of autonomic dysfunction has also 
been found in other ART-exposed, healthy populations 24,30<sup>24</sup><sup>24</sup>. Although, 
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admittedly, one of these populations consisted of slightly older individuals many of whom suffered from 
metabolic comorbidities and substance abuse 24. Clinical examination excluded dehydration, cardiac 
failure or any acute illness that could account for the postural hypotension found in 15% of the 
population. Adrenal insufficiency was not excluded as a possible confounder. We did not exclude those 
being treated for hypertension and diabetes as this could have biased our study results towards 
individuals free from chronic diseases of lifestyle – a population that is not representative of South 
African society at large. However, the notion of confounding is not absolutely certain because of the 
small number of hypertensives (8) and diabetics (2) within our cohort. Furthermore, only 2 out of the 10 
with the postural hypotension were taking anti-hypertensive treatment.  The SAS was useful in that it 
explored the other domains of autonomic function that our limited cardio-autonomic testing did not. 
Zilliox et al found an association between an increased SAS score or TIS and a reduced quantitative 
sudomotor axon reflex test (QSART) sweat volume 36, thus further validating the SAS as an important 
screening tool. Our most common autonomic symptoms were light headedness and cold feet. Robinson-
Papp et al found similar results despite their age and sex difference 24.  
Our study found that heart rate variability was the predominant autonomic sign. The characteristics of 
the HIV-positive groups with decreased heart rate variability in the studies by Askgaard et al and Lebech 
et al were strikingly comparable to our own cohort: median CD4 of 552 cells/µL and on ART for a median 
of 7.2 years, 99% of whom had suppressed viral loads27,28. And similar to these studies, there was no 
association between autonomic parameters and CD4 count and ART duration in our cohort. 
Interestingly, although there was no association between autonomic dysfunction and DSP, those with 
SDSP were more likely to have autonomic dysfunction than those without. The association between 
CASr and SDSP would suggest a common pathogenesis for this shared small fiber neuropathy. Whether 
the nature of this insult is immune regulated or as a result of direct ART toxicity is not clear.  
This study confirms that DSP and SDSP impair daily living. Although the median LEFS percentages in 
those with DSP and SDSP were relatively high implying that our cohort did not have marked functional 
impairment overall, these scores were significantly lower than those who did not have DSP or SDSP. In 
the American study by Galantino, participants with DSP obtained a median LEFS raw score of 39 (48.8%) 
which is considerably lower than our cohort with DSP15. This may be indicative of the resilience of our 
patients who come from a low socio-economic background. Higher TIS scores also seemed to adversely 
affect LEFS percentages in this cohort, although this inverse relationship was only moderately strong.   
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We believe our simple approach to diagnosing DSP and autonomic dysfunction by using bedside skills 
and tools will assist clinicians in screening for this common complication amongst HIV-infected patients 
attending resource-restricted community health care centers in South Africa. This will hopefully lead to 
prompt and appropriate treatment of symptomatic DSP and autonomic dysfunction thereby diminishing 
its negative affect on function and quality of life.  
Recommendations and Limitations 
Given the small sample size, it may be difficult to extrapolate these results to the wider ART-exposed 
population. Furthermore, under the current “Universal Test and Treat” policy, asymptomatic HIV-
infected patients with preserved CD4 counts are now receiving ART - a population that has not been 
extensively studied. Our cohort, however, is representative of a South African population that initiated 
ART during the advanced stages of HIV under the previous government-sponsored ART roll-out program. 
Clinicians must keep this difference in mind when dealing with the former group. 
A longitudinal analysis would have been useful to ascertain whether DSP or autonomic dysfunction was 
present prior to ART initiation, and if the prevalence and characteristics of these complications altered 
on long-term ART. We only enquired about current alcohol abuse; not previous alcohol abuse. We 
acknowledge that previous alcohol abuse may have been a confounder in those with DSP and autonomic 
dysfunction.  
The investigators did not use formal neurophysiological testing to confirm the diagnosis of DSP or 
autonomic dysfunction.  However, these tests assess large fiber function and are expected to be normal 
in small fiber neuropathies such as HIV-associated DSP. The validated neuropathy screening tools, BPNS 
and rTNS, can be used as guides for screening for DSP in the ART-exposed population.  
Conclusion 
DSP is prevalent in this community-based, HIV-infected cohort on ART ≥5years and can lead to 
functional impairment in some individuals. Autonomic dysfunction was associated with SDSP. DSP and 
SDSP impaired daily living. Further research on autonomic dysfunction and functional impairment in 
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Supplementary Tables  








BMI (kg/m²), mean (±SD) 28 (6.3) 27.6 (5.7) 29.9 (8.3) 0.23ᶧ 
SBP (mmHg), mean (±SD) 125.2 (20.2) 125.3 (20.5) 124.9 (19.5) 0.95ᶧ 
DBP (mmHg) mean (±SD) 78.3 (14.4) 78.5 (14.7) 77.2 (13.4) 0.77ᶧ 
hsCRP (mg/L), median (IQR) 4.5 (2.2-7.8) 4.6 (2.4-7.8) 3.6 (1.1-7.2) 0.44ˠ 
Fasting blood glucose (mmol/L), 
median (IQR) 
4.9 (4.5-5.4) 4.9 (4.5-5.4) 5.0 (4.6-5.3) 0.95ˠ 
Total cholesterol (mmol/L), 
median (IQR) 
4.5 (3.8-5.0) 4.5 (3.8-5.0) 4.6 (3.8-5.0) 0.99ˠ 
Triglycerides (mmol/L), median 
(IQR) 
0.9 (0.7-1.2) 0.9 (0.7-1.2) 0.94 (0.7-1.0) 0.59ˠ 
HDL (mmol/L), median (IQR) 1.5 (1.2-1.9) 1.4 (1.1-1.9) 1.7 (1.6-2.0) 0.09ˠ 
LDL (mmol/L), median (IQR) 2.4 (1.9-2.9) 2.4 (2.0-2.9) 2.5 (1.9-2.9) 0.70ˠ 
DSP, distal sensory polyneuropathy; BMI, Body mass index; SD, standard deviation; SBP, systolic blood 
pressure; DBP, systolic blood pressure; hsCRP, highly-sensitive C-reactive protein; IQR, interquartile 
range; HDL, high density lipoprotein; LDL, low density lipoprotein  
 
Table S2 Characteristics of participants with DSP (3signs) and without DSP (3 signs) 
Characteristic Total 
N=67 





Age (years), mean (±SD) 41.6 (8.6) 42.8 (36-47) 40.3 (8.5) 0.24ᶧ 
LEFS %, median (IQR) 95 (88.1-100) 93.8 (83.8-98.8) 97.5 (91.3-100) 0.15ˠ 
Current CD4 (cells/uL), mean 
(±SD) 
560.2 (236.5) 590.1 (264.2) 528.2 (202.5) 0.32ᶧ 
Viral suppression (<400 
copies/ml), N (%) 
56 (83.6) 30 (81.1) 26 (86.7) 0.54 
Viral load <20 copies/ml , N % 50 (74.6) 26 (70.3) 24 (80) 0.36 
Previous TB, N (%) 39 (58.2) 25 (67.6) 14 (46.7) 0.085 
DSP, distal sensory polyneuropathy; SD, standard deviation; LEFS, lower extremity functional scale; TB, 













Women, N (%) 21 (87.5) 29 (96.7) 0.20* 
Age (years),  mean (±SD) 42.5 (10.5) 41.2 (7.1) 0.61ᶧ 
LEFS % , median (IQR) 88.8 (81.3-97.5) 96.3 (90.0-98.8) 0.04ˠ 
SAS score, median (IQR) 4 (1-5) 2 (1-3.8) 0.063 
SAS total impact score, median 
(IQR) 
10 (2.8-15) 3 (2-7.8) 0.0008 
Weight (kg),  mean (±SD) 70 (15.4) 70.5 (15.9) 0.92ᶧ 
Height (m), median (IQR) 1.62 (1.55-1.65) 1.59 (1.55-1.62) 0.44 ˠ 
BMI (kg/m²), mean (±SD) 27.5 (6.6) 27.6 (5.1) 0.94ᶧ 
SBP (mmHg), mean (±SD) 127.5(20.8) 123.6 (20.5) 0.50ᶧ 
DBP (mmHg) mean (±SD) 80.9 (15.5) 76.6 (14.0) 0.29ᶧ 
Current CD4 (cells/uL), mean 
(±SD) 
517 (373-581) 602.9 (271.5) 0.27ᶧ 
Viral suppression (<400 
copies/ml), N (%) 
19 (79.2) 25 (83.3) 0.70* 
Viral load <20 copies/ml , N % 18 (75) 20 (66.7) 0.51* 
ART duration (years), median 
(IQR) 
6.5 (5.75-10.5) 8 (6.0-9.0) 0.85ˠ 
D-Drugs, N (%) 2 (8.3) 1 (3.3) 0.43* 
Efavirenz, N (%) 13 (54.17) 17 (56.67) 0.75* 
Isoniazid, N (%) 5 (20.83) 4 (13.33) 0.46* 
Previous TB, N (%) 16 (66.67) 16 (53.33) 0.32* 
hsCRP (mg/L), median (IQR) 6.3 (3.23-10.83) 4.2 (2.2-6.9) 0.26 ˠ 
Fasting blood glucose (mmol/L), 
median (IQR) 
4.9 (4.5-5.18) 5.1 (4.6-5.4) 0.48ˠ 
Total cholesterol (mmol/L), 
median (IQR) 
4.6 (3.7- 5.15) 4.3 (3.9-4.7) 0.73ˠ 
Triglycerides (mmol/L), median 
(IQR) 
0.87 (0.7- 1.2) 0.9 (0.8-1.1) 0.75ˠ 
HDL (mmol/L), median (IQR) 1.44 (1.2-1.9) 1.4 (1.1-2.0) 0.73ˠ 
LDL (mmol/L), median (IQR) 2.38 (2-3.2) 2.4 (2.0-2.8) 0.42ˠ 
SDSP, symptomatic distal sensory polyneuropathy; ADSP, asymptomatic distal sensory polyneuropathy; 
LEFS, lower extremity functional scale; SAS, survey of autonomic symptoms; IQR, interquartile range; SD, 
standard deviation; BMI, Body mass index; SBP, systolic blood pressure; DBP, systolic blood pressure; 
ART, anti-retro viral therapy; D-Drugs, Stavudine (D4T) or didanosine (DDI);  hsCRP, highly-sensitive C-
reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein ; P-values derived by *z-test, 




Table S4 LEFS and Autonomic characteristics of the total cohort, DSP 2-signs and no DSP 







LEFS % , median (IQR) 95 (88.1 -100) 93.8 (85.6-98.8) 100 (94.4-100) 0.039ˠ 
CASr, N(%) 38 (56.7) 32 (59.3) 6 (46.2) 0.4 
SAS score, median (IQR) 2 (1-4) 2 (1-4) 1 (0-4) 0.22 
SAS total impact score, median 
(IQR) 
6 (1-10.5) 6.5 (2-10.8) 2 (0-8) 0.18 
DSP, distal sensory polyneuropathy; LEFS, lower extremity functional scale; IQR, interquartile range; 



































r = 0.34 ; p = 0.002





















































































































Lower Extremity Functional Scale Questions 
 
Figure S2 Line graph depicting the association between DSP, SDSP and CASr. The “no SDSP” classification does not only 
consist of asymptomatic DSP but includes all patients who did not meet criteria for DSP or SDSP. DSP, distal sensory 





Figure S3 Frequency of impaired LEFS (lower extremity functional scale) 










Figure S4 Scatter plot depicting the association between DSP, SDSP and LEFS. The “no SDSP” classification does not 
only consist of asymptomatic DSP but includes all patients who did not meet criteria for DSP or SDSP. DSP, distal 
























Figure S6 Correlation between LEFS% (lower extremity functional scale ) and TIS (total impact score) 
S7 
Figure S7 Correlation between LEFS% (lower extremity functional scale) and 
BPNS (brief peripheral neuropathy screen) Symptom Severity Grade 
S8 
Figure S8 Correlation between LEFS% (lower extremity functional scale ) and TNSr (reduced 




Patient information and consent document: Understanding the role of 
inflammation and the metabolic syndrome in aging in a South Africans with HIV-
infection on ART. 
Researchers: Dr M Borkum, Dr S Mazondwa, Dr M Dudley 
Supervisors: Dr N Wearne, Prof J Heckmann, Dr J Dave, Prof M Combrinck 
You were previously part of a research project studying the effects of antiretroviral 
therapy (ART) on your body’s glands, nerves, blood sugar and cholesterol levels. That 
study occurred over a 2 year period and you attended at least one of those visits. Here 
we are asking you whether you would participate in one 5-year follow-up study visit. If 
we do obtain funding we may contact you again in 5 years’ time for a 10 year study visit. 
Here we would like to give you information about the previous study results as well as 
what we plan to do in this 5 year visit. Please remember that you do not have to 
participate in the research and you may talk to anyone you feel comfortable with about 
the research before deciding. 
 
WHAT HAVE WE LEARNT FROM THE FIRST 2 YEARS (McHAART STUDY) 
 
As you know, ART cannot cure HIV/AIDS but it helps fight the human immunodeficiency 
virus and has helped patients feel a lot better. ART has made HIV-infection a chronic 
disease and we anticipate that most people will become older and remain on ART for 
many years. However, ART also has side-effects. Some of these side-effects include 
the development of diabetes, cholesterol problems, changes in body shape (usually 
either increased or decreased fat in certain areas of the body) and damage to the 
nerves in your feet.  Very little is known about these problems in HIV-positive individuals 
in South Africa. In our initial study we found very few patients developed diabetes or 
cholesterol problems despite the persons gaining weight. Also, during the 2 years of 
study we found the blood pressure measurements remained normal. Many people who 
had pain in their feet before ART did very well on ART and in some the pain went away 
completely. However, a small proportion developed numbness in the feet as time went 
by.  
 
In this study we would like to see what happens 5 years after starting ART. This would 
help the doctors and patients to understand the side-effects of ART after a longer 







We will focus less on body fat and more on the heart, brain and kidneys. The study 
involves two mornings of testing in E7 and G13, New Groote Schuur Hospital (3 hours 
of testing in total). This will include a heart ECG test and blood pressure test lying and 
standing. We will also put a 24-hour blood pressure machine on your arm which we 
would like you to return the next morning. 
We will again be studying the blood sugar and cholesterol tests although bloods will 
only be taken at 2 time points. We will also ask for a urine specimen on 2 mornings- the 
morning of the tests and the morning when the blood pressure machine is returned. 
 
We will perform the nerve testing (as previously) and a slightly longer version of 
memory and brain function testing (20-30 minutes). We will ask some questions about 
your general health and how you copy in your day to day life.  
 
The study visit will extend over 2 mornings; one short visit of 60 minutes (urine and 
memory tests) and one longer visit of 2.5 hours (blood sampling, heart, nerve and urine 
tests.  
 
WHAT WILL HAPPEN IF I AGREE TO PARTICIPATE? 
The same as previously: We will ask you not to eat or drink anything from 10 pm the 
night before your appointment.  At your appointment the doctor will examine you (your 
blood pressure, ECG heart tests, nerve test to look for any damage to the nerves in 
your feet) and will insert a drip cannula (a small plastic device that stays inside the vein 
allowing all further blood samples to be taken from it thus avoiding any further need for 
needle pricks). Using a syringe a sample of blood (~ 25 ml, 1 tablespoon) will be taken 
from the cannula.  After taking the blood sample, you will be asked to drink a glass of 
water with glucose, a form of sugar.  A further blood sample will be taken at 2 hours 
(120 min) after completing this drink. The blood will be sent to a laboratory and tested 
for glucose, insulin and cholesterol.  Some of the blood will be frozen and kept for 
testing at a later stage.  Whilst waiting for your blood samples to be taken the study staff 
will do the following: a) using a tape measure they will measure your body waist and 
your height b) take blood pressure measurements c) measure your body weight using a 
scale.   
While you are waiting you will be asked to complete a questionnaire about symptoms 
and about how you are able to function in your everyday life. 
Following this will assess the nerves in your feet and perform the 3 minute brain 
function test testing memory, rapid finger and hand movements. 
New assessments: A neuropsychologist (under supervision of Prof Combrinck), will 
perform another set of brain function tests in a quiet room for about 20-30 minutes. This 
will include reading red and green cards (Stroop test), linking numbers or letters with a 
42 
 
pencil (trail-making), putting little pegs/pins into tiny holes (testing fine movements) and 
memory. This test will be after you have eaten (either day one or two). 
A 24 hour ambulatory BP cuff will be placed on your arm and will record your BP while 
you are walking and sleeping. It will be removed the next morning. You will give a urine 
sample in the morning before you are free to leave. 
All transport costs to the hospital will be covered. On the first day you will receive a 
lunch packet with a sandwich and juice. We will provide each person R250 for 
participating in this research to cover your time at the hospital and transport home. After 
the first day we will provide you with R100 and after you return the second day with the 
BP machine we will give you the remaining R150. 
The study staff will also review all of your previous clinic records including all of your 
previous blood test results (including HIV status, viral load, CD4 count, liver function, 
kidney function, etc)   
 
WHAT ARE THE POSSIBLE DISCOMFORTS OF PARTICIPATING IN THE STUDY? 
Having blood taken will be the only discomfort in this study. Risk of infection will be 
minimized by using sterile procedures, and all blood samples will be taken by suitably 
qualified persons.   
 
WHAT ARE THE POSSIBLE BENEFITS? 
If you are found to have any of side-effects of ART then arrangements will be made for 
you to be seen at a hospital where doctors specially trained in looking after these 
problems will look after you.  This study will help doctors find these problems early 
therefore the required investigation and treatment can be done before any further 
problems arise. 
 
DO I HAVE TO PARTICIPATE? 
You do not have to participate in this study.  Your participation is voluntary and if you 
agree to participate then you will be required to sign a form.  You can withdraw from the 
study at anytime and this will in no way affect your treatment in the future. 
 
WILL THE INFORMATION REMAIN CONFIDENTIAL? 
Your records will only be viewed by your doctors and people involved in this study.  
Your details will not be made available to anybody not involved in this study.  Although 
absolute confidentiality cannot be guaranteed the staff involved in this study will strive to 




CONTACT DETAILS OF STUDY STAFF 
Should you have any questions then please contact Dr Megan Borkum or Dr Sim 
Mazondwa   
Ph: 072 246 5633 
Principal Investigators: Wearne and Heckmann 
Organisation: University of Cape Town 
 
I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions that I have asked have 
been answered to my satisfaction. I consent voluntarily to participate as a 
participant in this research. 
 
Name of Participant  ___________________ 
 





Name of Doctor taking consent  ___________________ 
 















LEFS-Modified (Journal of Social Aspects of HIV/AIDS vol 11 (1), 2014)  
Study number_______   Date : 
___/___/201__ 
Sinomdla wokwazi ukuba ingaba ufumana ubunzima ekwenzeni lemisebenzi ikhankanywe 
ngezantsi ngenxa  yengxaki ngelungu elingezantsi lomzimba wakho. Sekilisha inombolo 
kumgca ngamnye ongqamelana/ongqinelana nempendulo yakho efanelekileyo. 











1. Bokwenza eminye yemisebenzi yakho odla 
ngokuyenza (umz. Umsebenzi okungenisela imali 
okanye nokuba ngowuphi na umsebenzi 
owenzayo), umsebenzi wasekhaya okanye 
umsebenzi wesikolo 
0 1 2 3 4 
2. Bokwenza izinto odla ngothanda ukuzenza, 
izinto ezikonwabisayo okanye imidlalo, umz. ukuya 
emitshatweni, ecaweni okanye ukutyelela 
abahlobo 
0 1 2 3 4 
3. Bokuya/bokuphuma kwigumbi lokuhlambela 
okanye lokuhlamba 
0 1 2 3 4 
4. Bokuhamba phakathi kwamagumbi 
(njengokusuka kwigumbi lakho lokulala usiya 
kwigumbi langasese, ekhitshini, njalo njalo.) 
0 1 2 3 4 
5. Bokunxiba nokuba sesiphina isihlangu okanye 
iikawusi, kuquka nezilipasi okanye izihlangu 
ezivulekileyo 
0 1 2 3 4 
6. Bokuchopha (umz. Ukuchopha ethoyilethi 
okanye ukuchopha nokuba kuphi) 
0 1 2 3 4 
7. Bokuphakamisa into, enjengengxowa yegrosari 
okanye imbhombhozi encinci yeelitha eziyi-5 ezele 
ngamanzi, ibhaskethi yeetapile, njl njl., ephantsi 
0 1 2 3 4 
8. Bokwenza imisebenzi engekho nzima ekhayeni 
lakho (enjengokupheka, ukucoca indlu, ukondlula 
ibhedi okanye nokuba ngowuphi na umsebenzi olula 
ekhaya) 
0 1 2 3 4 
9. Bokwenza imisebenzi enzima ekhaya 
(enjengokomba, ukuphakamisa ingxowa enzima 
yeetapile, imbhombhozi yamanzi yeelitha 
eziyi-20, ukususa izinto ezinzima, njl njl.) 
0 1 2 3 4 
10. Bokungena okanye bokuhlika emotweni 
okanye eteksini 





11. Bokusuka endlwini yakho usiya kwindlu 
kammelwane wakho okanye ukuhamba iimitha 
eziyi-100 
0 1 2 3 4 
12. Bokuhamba ikhilomitha, umzekelo ukuya 
emarikeni/evenkileni, ecaweni okanye 
nakweyiphi na indawo 
0 1 2 3 4 
13. Bokunyuka usehla kwizitezi eziyilishumi 
okanye ukuhamba kwindlela enyukayo okanye 
kumhlaba ongagudanga okanye ongekho tyaba 
0 1 2 3 4 
14. Bokuma iyure 0 1 2 3 4 
15. Bokuhlala iyure, njengaxa usecaweni, 
eteksini okanye ezintlanganisweni 
0 1 2 3 4 
16. Bokuhamba ngokukhawuleza kumhlaba othe 
tyaba 
0 1 2 3 4 
17. Bokuhamba okanye bokubaleka kumhlaba 
ongagudanga/ongathanga tyaba 
0 1 2 3 4 
 












19. Bokuma ngokukhawuleza eva kokuchopha 0 1 2 3 4 
20. Bokujika ebhedini 0 1 2 3 4 
 
Activity Unable to 
perform 
activity  









1. Any of your usual work, (e.g. work that earns 
you income or any other work you do) 
housework or school activities 
0 1 2 3 4 
2. Your usual hobbies, recreational or sporting 
activities, e.g. attending weddings, church or 
visiting friends 
0 1 2 3 4 
3. Getting into or out of the bath/taking bath 0 1 2 3 4 
4. Walking between rooms (such as walking from 
your room to toilet, bathroom, kitchen, etc) 
0 1 2 3 4 
5. Putting on any kind shoes or socks, including 
slippers or open shoes, if applicable 
0 1 2 3 4 
6. Squatting (e.g. squatting on pit latrine/doing 
any squatting activity) 
0 1 2 3 4 
7. Lifting an object, like a bag of groceries or a 
small container like a 5-litre container full of 
water, basket of potatoes, etc., from floor 
0 1 2 3 4 
8. Performing light activities around your home 
(such as preparing a meal, cleaning a house, 
making a bed or any other light activity at 
home) 



















9. Performing heavy activities around your home 
(digging, lifting a heavy bag of potatoes, 20-litre 
gerrican of water, shifting a big items, etc. 
0 1 2 3 4 
10. Getting into or out of a car/taxi 0 1 2 3 4 
11. Walking across from your home to a 
neighbour’s or walk about 100m across 
0 1 2 3 4 
12. Walking a km, such as going to market, church 
or any other place 
0 1 2 3 4 
13. Going up or down 10 stairs (about 1 flight of 
stairs) or walking up a steep and irregular 
ground 
0 1 2 3 4 
14. Standing for 1 hour 0 1 2 3 4 
15. Sitting for 1 hour, like when in church, taxi or 
meetings 
0 1 2 3 4 
16. Fast walking on even ground 0 1 2 3 4 
17. Fast walking/running on uneven ground 0 1 2 3 4 
18. Making sharp turns while walking/running very 
fast 
0 1 2 3 4 
19. Standing up fast from squatting 0 1 2 3 4 
20. Turning in bed 0 1 2 3 4 
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Study number:______________________  Date: ___/____/201__ 
Uluhlu 1.   Uphononongo ngeempawu (okanye izigulo) ezizenzekalayoa  
 Q1a. Ingaba wakha 




zintandathu zidlulileyo?  
1 = Ewe; 0 = Hayi 
Q1b. Ukuba uphendule u- 
Ewe kuMbuzo 1a, ungathi 
ezimpawu zikukhathaza 
kangakanani. 1 =Nakanye;  
2= Kancinci;  
3 = Ngamanye amaxesha;  
4 = Manqapha- nqapha;  
5 = Kakhulu 
Iimpawu/iingxaki zempilo 
1.Ingaba unesiyezi? 1 = Ewe     0 = Hayi 1 2 3 4 5 
2.Ingaba unomlomo owomileyo okanye 
amehlo omileyo? 
1         0 1 2 3 4 5 
3. Ingaba iinyawo zakho zimpatsha-mpatsha 
okanye zibhlowu? 
1         0 1 2 3 4 5 
4. Ingaba iinyawo zakho 
ziyabanda kunomzimba wakho wonke? 
1         0 1 2 3 4 5 
5. Ingaba kwehlile na ukubila 
okusezinyaweni zakho xa ukuthelekisa 
nokubila okusemzimbeni wakho? 
1         0 1 2 3 4 5 
6. Ingaba kwehlile okanye 
abukho na ukubila ezinyaweni zakho 
(umzekelo, emva kokuzilolonga okanye 
emva kwemozulu eshushu)? 
1         0 1 2 3 4 5 
7. Ingaba kwandile na ukubila 
ezandleni zakho xa ukuthelekisa nokubila 
okusemzimbeni wakho uwonke? 
1         0 1 2 3 4 5 
8.Ingaba unesicaphucaphu, uyagabha, 
okanye uyaqunjelwa emva kokutya ukutya 
okuncinci? 
1         0 1 2 3 4 5 
9. Ingaba unokuhambisa okungapheliyo 
(uhambisa amatyeli angaphezu 
kwesithathu)?  
1         0 1 2 3 4 5 
10. Ingaba unokuqhingwa okungapheliyo 
(utawa kanye ngemini)? 
1          0  1 2 3 4 5 
11. Ingaba uyathontsiza xa ugqiba 
ukuchama?  
1          0 1 2 3 4 5 
12. Ingaba unengxaki yokuvukelwa (oku 
kuphathelele kumadoda)? 
1          0 1 2 3 4 5 
 
Total number of symptoms _________ total severity of symptoms_________ 
 Survey of Autonomic Symptomsa 
 Q1a. Have you had any Q1b. If you answered yes 




of the following health 
symptoms during the 
past 6 months? (1 = 
Yes; 0 = No) 
in Q1a, how much would 
you say the symptom 
bothers you? (1 = Not at 
all; 2 = A little; 3 = Some; 4 
= A moderate amount; 5 = 
A lot) 
Symptom/health problem 
1. Do you have lightheadedness? 1   0 1 2 3 4 5 
2. Do you have a dry mouth or dry eyes? 1   0 1 2 3 4 5 
3. Are your feet pale or blue? 1   0 1 2 3 4 5 
4. Are your feet colder than the rest of 
your body? 
1   0 1 2 3 4 5 
5. Is sweating in your feet decreased 
compared to the rest of your body? 
1   0 1 2 3 4 5 
6. Is sweating in your feet decreased or 
absent (for example, after exercise or 
during hot weather)? 
1   0 1 2 3 4 5 
7. Is sweating in your hands increased 
compared to the rest of your body?  
1   0 1 2 3 4 5 
8. Do you have nausea, vomiting, or 
bloating after eating a small meal? 
1   0 1 2 3 4 5 
9. Do you have persistent diarrhea 
(more than 3 loose bowel movements 
per day)? 
1   0  1 2 3 4 5 
10. Do you have persistent constipation 
(less than 1 bowel movement every 
other day)? 
1   0 1 2 3 4 5 
11. Do you have leaking of urine? 1   0 1 2 3 4 5 
12. Do you have difficulty obtaining an 
erection (men)? 
1   0 1 2 3 4 5 
 
a Number of symptoms reported: ____(sum of column A, 0-12 for men and 0-11 for women); total 
symptom impact score: ___(sum of column B, 0-60 for men and 0-55 for women). 
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